- CMS manages the federal health insurance program.
- CMS is implementing temporary coverage for GLP-1 drugs for Medicare patients.
- Novo Nordisk is providing Wegovy to Medicare patients through the Medicare GLP-1 Bridge program.
A new Medicare program is expected to boost prescription volumes for Novo Nordisk drugs.
1 report, 1 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A new Medicare program is expected to boost prescription volumes for Novo Nordisk drugs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novo Nordisk
Danish pharmaceutical company
-
Medicare
US federal health insurance
Related events
- Medicare prescription changes affect Novo Nordisk's revenue outlook, coinciding with a Deutsche Bank stock downgrade.
- Medicare has approved coverage for obesity drugs from Novo Nordisk and Eli Lilly.
- Novo Nordisk and Eli Lilly are utilizing physician networks in Texas, including Carlos Campos, to promote their weight-loss drugs.
- Novo Nordisk launched insulin in the US market.
- Galvani and Fitzpatrick co-authored a study finding that Medicare-level payments reduce healthcare costs.